News
Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...
Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.
MariTide is designed to combine the effects of glucagon-like peptide-1 (GLP-1) receptor activation with glucose-dependent ...
Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...
A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.
Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results